Scott T. Tagawa, MD, MS, FACP, Weill Cornell Medicine

Articles

Dr. Tagawa on the Evolution of ADCs in mCRPC

July 14th 2023

Scott Tagawa, MD, MS, FACP, discusses the evolution of antibody-drug conjugates in metastatic castration-resistant prostate cancer, as well as potential future targets for ADC development in this space.

Dr. Tagawa on the Evolution and Selection of PARP Inhibitors in mCRPC

May 30th 2023

Scott Tagawa, MD, MS, FACP, discusses the evolution of PARP inhibitor use in metastatic castration-resistant prostate cancer and available PARP inhibitors for molecularly-selected patients in this space.

Dr. Tagawa on the Investigation of 225Ac-J591 and 177Lu-PSMA-I&T in mCRPC

April 12th 2022

Scott T. Tagawa, MD, MS, FACP, discusses the investigation of 225Ac-J591 and 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer in a phase 1/2 trial.

Optimizing Use of PSMA PET Imaging and PSADT in Prostate Cancer

March 30th 2022

Shared insight on the respective roles of PSMA-PET imaging and PSA doubling time in the current prostate cancer treatment paradigm.

Overview of Improvements in Prostate Cancer Management

March 30th 2022

Broad discussion on the evolution of care in prostate cancer from both the therapeutic and imaging standpoints.

Dr. Tagawa on Utilizing Bone-Targeting Radium-223 in Prostate Cancer

March 16th 2022

Scott T. Tagawa, MD, MS, FACP, discusses the use of radium-223 in prostate cancer.

Genomic Profiling Assays in Metastatic Urothelial Cancer

November 24th 2021

The significance of using broad genomic profiling tests to help detect promising biomarkers in metastatic urothelial cancer.

Multidisciplinary Care in Metastatic Urothelial Cancer

November 24th 2021

An overview of the types of health care professionals who may help manage patients with metastatic urothelial cancer throughout their disease course.

Barriers to Molecular Testing in Metastatic Urothelial Cancer

November 17th 2021

A discussion on molecular testing in the community and recommendations that can address barriers.

Molecular Testing in Metastatic Urothelial Cancer During COVID-19

November 17th 2021

The impact of the COVID-19 pandemic on rates of molecular testing used by community oncologists who care for patients with urothelial cancer.

Tissue and Liquid Biopsies in Metastatic Urothelial Cancer

November 10th 2021

A discussion on current prognostic and predictive testing assays used to detect FGFR mutations in patients with metastatic urothelial cancer (mUC).

Testing for FGFR Mutations in Metastatic Urothelial Cancer

November 10th 2021

A discussion on current prognostic and predictive testing assays used to detect FGFR mutations in patients with metastatic urothelial cancer (mUC).

Nonmetastatic CRPC: Treatment Selection

September 20th 2021

An in-depth discussion regarding experience treating nonmetastatic castration-resistant prostate cancer (CRPC) with apalutamide, enzalutamide, and darolutamide, and factors that impact treatment selection.

Advances in Nonmetastatic CRPC

September 20th 2021

An overview of drug approvals for nonmetastatic castration-resistant prostate cancer (CRPC), and discussion regarding the potential utility of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) to guide treatment decisions.

Oral GnRH Antagonist Therapy for mCSPC

September 13th 2021

Implications of treating patients with metastatic castration-sensitive prostate cancer with relugolix, an oral GnRH antagonist.

mCSPC: Applying New Data into Clinical Practice

September 13th 2021

Recommendations for integrating treatment advances in metastatic castration-sensitive prostate cancer into everyday practice.

Triple Therapy Approaches for mCSPC

September 7th 2021

Potential implications for treating metastatic castration-sensitive prostate cancer with triple therapy based on recently reported data.

ADT Monotherapy in mCSPC

September 7th 2021

The rationale for treating metastatic castration-sensitive prostate cancer with androgen deprivation therapy as monotherapy as the field advances with newer combination approaches.

Treatment Advances in mCSPC

August 30th 2021

Treatment Advances in mCSPC

Dr. Tagawa on the Integration of PSMA-Targeted Agents in Prostate Cancer

August 23rd 2021

Scott Tagawa, MD, MS, FACP, discuss the integration of targeted agents in prostate cancer.